CCL

Összesen 2 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM067427
035-os BibID:(WoS)000401138800008 (Scopus)85007256365
Első szerző:Combe, Bernard
Cím:2016 update of the EULAR recommendations for the management of early arthritis / Bernard Combe, Robert Landewe, Claire I. Daien, Charlotte Hua, Daniel Aletaha, Jose María Álvaro-Gracia, Margôt Bakkers, Nina Brodin, Gerd R. Burmester, Catalin Codreanu, Richard Conway, Maxime Dougados, Paul Emery, Gianfranco Ferraccioli, Joao Fonseca, Karim Raza, Lucía Silva-Fernández, Josef S. Smolen, Diana Skingle, Zoltan Szekanecz, Tore K. Kvien, Annette van der Helm-van Mil, Ronald van Vollenhoven
Dátum:2017
ISSN:0003-4967
Megjegyzések:Objectives Since the 2007 recommendations for the management of early arthritis have been presented, considerable research has been published in the field of early arthritis, mandating an update of the 2007 European League Against Rheumatism (EULAR) recommendations for management of early arthritis.Methods In accordance with the 2014 EULAR Standardised Operating Procedures, the expert committee pursued an approach that was based on evidence in the literature and on expert opinion. The committee involved 20 rheumatologists, 2 patients and 1 healthcare professional representing 12 European countries. The group defined the focus of the expert committee and target population, formulated a definition of ♭management' and selected the research questions. A systematic literature research (SLR) was performed by two fellows with the help of a skilled librarian. A set of draft recommendations was proposed on the basis of the research questions and the results of the SLR. For each recommendation, the categories of evidence were identified, the strength of recommendations was derived and the level of agreement was determined through a voting process.Results The updated recommendations comprise 3 overarching principles and 12 recommendations for managing early arthritis. The selected statements involve the recognition of arthritis, referral, diagnosis, prognostication, treatment (information, education, pharmacological and non-pharmacological interventions), monitoring and strategy. Eighteen items were identified as relevant for future research.Conclusions These recommendations provide rheumatologists, general practitioners, healthcare professionals, patients and other stakeholders with an updated EULAR consensus on the entire management of early arthritis.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Annals Of The Rheumatic Diseases. - 76 : 6 (2017), p. 948-959. -
További szerzők:Landewé, Robert Daien, Claire I. Hua, Charlotte Aletaha, Daniel Álvaro-Gracia, Jose María Bakkers, Margôt Brodin, Nina Burmester, Gerd R. Codreanu, Catalin Conway, Richard Dougados, Maxime Emery, Paul Ferraccioli, Gianfranco Fonseca, João Raza, Karim Silva-Fernández, Lucía Smolen, Josef S. Skingle, Diana Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Kvien, Tore K. van der Helm-van Mil, Annette van Vollenhoven, Ronald
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM088829
Első szerző:Pavelka, Karel
Cím:Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate : a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients / Pavelka Karel, Szekanecz Zoltán, Damjanov Nemanja, Anić Branimir, Tomšič Matija, Mazurov Vadim, Maksimovic Marija, Nagy Orsolya, Świerkot Jerzy, Petranova Tzvetanka, Veldi Tiina, Baranauskaitè Asta, Codreanu Catalin, Andersone Daina, Fleischmann Roy
Dátum:2020
ISSN:1745-1981 1740-4398
Megjegyzések:Background: In the randomized, phase III, global SELECTCOMPARE study, upadacitinib 15 mg demonstrated efficacy at week 12 versus placebo and adalimumab with methotrexate (MTX) in patients with rheumatoid arthritis and inadequate response to MTX, which was maintained over 48 weeks. This post hoc analysis of SELECT-COMPARE reports the efficacy and safety of upadacitinib in Central and Eastern European (CEE) patients. Methods: Patients were randomized 2:2:1 to upadacitinib 15 mg once daily, placebo, or adalimumab 40 mg every other week, and continued MTX. Efficacy and safety were assessed through 48 weeks. Primary endpoints were the achievement of ?20% improvement in American College of Rheumatology response criteria and Disease Activity Score in 28 joints with C-reactive protein <2.6 responses at week 12 for upadacitinib versus placebo. No statistical comparisons were conducted. Results: A total of 596 patients from 12 CEE countries were randomized. At week 12, a numerically greater proportion of patients receiving upadacitinib versus placebo or adalimumab achieved ?20% improvement in American College of Rheumatology response criteria (72% versus 33% and 59%), Disease Activity Score in 28 joints with C-reactive protein <2.6 (26% versus 4% and 11%), low disease activity and remission, and improved physical function, with results maintained over 48 weeks. Upadacitinib treatment numerically inhibited structural progression versus placebo at week 26. Serious infection and herpes zoster rates were numerically higher with upadacitinib versus adalimumab (2.7 versus 1.7 and 2.3 versus 1.1 events/100 patient-years, respectively) over 48 weeks. Conclusion: Consistent with the global population of patients with rheumatoid arthritis and an inadequate response to MTX, in CEE patients, upadacitinib 15 mg demonstrated clinical and functional improvements versus placebo and adalimumab, radiographic improvements versus placebo, and reasonable safety, over 48 weeks.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Eastern Europe
rheumatoid arthritis
safety
treatment efficacy
upadacitinib
Megjelenés:Drugs in Context. - 9 (2020), p. 1-15. -
További szerzők:Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Damjanov, Nemanja Anic, Branimir Tomšič, Matija Mazurov, Vadim Maksimovic, Marija Nagy Orsolya Świerkot, Jerzy Petranova, Tzvetanka Veldi, Tiina Baranauskaitè, Asta Codreanu, Catalin Andersone, Daina Fleischmann, Roy
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1